Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On Track To Approval, Alkermes Hopes ALKS-5461 Can Change Future Of Depression Therapy

Executive Summary

The novel opioid-system antidepressant is being positioned for adjunctive therapy on top of SSRIs, but Alkermes is eyeing other indications, and better ways to stratify and treat depressed patients.

Advertisement

Related Content

J&J Seeks A Priority Review For Depression Drug Esketamine
ICER’s 2019 Agenda Includes CAR-T Therapy, Drugs For Depression, Arthritis, AMD
J&J's Mixed Phase III Data For Esketamine Highlight Challenges In Resistant Depression
FDA Reversal Puts Alkermes Depression Drug Back On Track For January Approval
Opioids And Psychic Pain: Alkermes Uses High-Profile Stage To Highlight Depression Drug
If Alkermes Antidepressant Can Get Past FDA, The Market Might Be There

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123232

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel